Below is a chart for Sorrento Therapeutics (Nasdaq SRNE). The two major inflection points (December 2015 & July 2015) correspond to the inking of ''strategic' agreements and collaborations with Nantventures. Our agreement is expected to be inked by year end - this explains the subdued reaction so far. Add a Trump (biotech-friendly) victory to the mix and we have our 100 bagger.
Good luck to all faithful holders (and apologists too)
BLT Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
